What The Maternal Fetal ScreenSM | T1 Screens For
The chromosome abnormalities screened for in this test including:
Preeclampsia is a serious disease related to high blood pressure. It can happen to any pregnant woman during the second half of her pregnancy. When it results in the delivery of your baby before 34 weeks’ gestation, it is called “early onset preeclampsia,” and is often more dangerous to you and your baby.
NTD also offers stand-alone preeclampsia screening that does not include a risk assessment for Down syndrome, Trisomy 18 (Edwards Syndrome), or Trisomy 13 (Patau Syndrome).
Y Chromosome Assessment
Y chromosome assessment is an option available to patients who are pregnant with one baby that will assess the presence or absence of the Y chromosome. The presence of a Y chromosome is predictive of a male baby, while the absence of the Y chromosome typically means the baby is female. The result of this added evaluation will further refine your risk analyses for Down syndrome, Trisomy 18, Trisomy 13 and early onset preeclampsia.
Other Obstetric Complications
By analyzing the biological markers in mom’s blood, Maternal Fetal ScreenSM | T1 casts a wide net and also offers insight into other maternal and fetal issues, such as aneuploidy, preeclampsia, low birth weight, fetal loss, and stillbirth.
*Information provided if second trimester screening is included.
The Advantages of Free Beta hCG:
NTD Eurofins is the only laboratory that utilizes free beta hCG in their prenatal screening protocol. The use of free beta hCG in screening for Down syndrome and other chromosomal abnormalities has been demonstrated to be more effective than intact or total hCG. Intact/total hCG, while an effective second trimester marker, is far less effective during the first trimester.
Y Chromosome Assessment
Turn around time: Results can be expected 2-5 days from the time the sample is received at the laboratory.
Learn more about why NTD Eurofins has been the laboratory to trust for over 30 years.Learn More
Our Goal is to Educate and Empower
Know your choices, understand your options, and talk you your healthcare provider about the best prenatal screening program for you.Learn more
Cell free DNA is extracted from the plasma of whole blood. The isolated cell-free DNA contains a mixture of fetal DNA and maternal DNA. The presence of Y chromosome DNA from the fetal DNA is detected by PCR using Y chromosome specific primer-probe set. Y chromosome result is used in the analyte adjustment for risk assessment. The detection of Y chromosome assay has been validated for a minimum presence of 4% fetal fraction in the cell free DNA extraction. Therefor failure to detect Y chromosome signal may occur when there is less than 4% fetal fraction. Though this assay is highly sensitive, other possible diagnostic errors include sample mix-ups, rare genetic variants that could interfere with the analysis and other sources of error.